{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:05Z","timestamp":1793119685643,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Science and Technology Program of Xiangyang, China","award":["2019YL09"],"award-info":[{"award-number":["2019YL09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12012-025-10051-1","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:17:50Z","timestamp":1754486270000},"page":"1616-1633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database"],"prefix":"10.1007","volume":"25","author":[{"given":"Long","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Nan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"2","key":"10051_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","volume":"36","author":"YQ Sun","year":"2015","unstructured":"Sun, Y. Q., Huang, H., Chen, J., Li, J. Y., Ma, J., Li, J., et al. (2015). Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: A multicenter, prospective, observational study in China. Tumor Biology, 36(2), 757\u2013767. https:\/\/doi.org\/10.1007\/s13277-014-2649-7","journal-title":"Tumor Biology"},{"issue":"3","key":"10051_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12275-016-0647-8","volume":"54","author":"JY Kim","year":"2016","unstructured":"Kim, J. Y. (2016). Human fungal pathogens: Why should we learn? Journal Of Microbiology (Seoul, Korea), 54(3), 145\u2013148. https:\/\/doi.org\/10.1007\/s12275-016-0647-8","journal-title":"Journal Of Microbiology (Seoul, Korea)"},{"issue":"3","key":"10051_CR3","doi-asserted-by":"publisher","first-page":"106518","DOI":"10.1016\/j.ijantimicag.2022.106518","volume":"59","author":"A Ahmadi","year":"2022","unstructured":"Ahmadi, A., Mohammadnejadi, E., Karami, P., & Razzaghi-Asl, N. (2022). Current status and structure activity relationship of privileged azoles as antifungal agents (2016\u20132020). International Journal of Antimicrobial Agents, 59(3), 106518. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106518","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"8","key":"10051_CR4","doi-asserted-by":"publisher","first-page":"11333","DOI":"10.3390\/molecules190811333","volume":"19","author":"Y Wang","year":"2014","unstructured":"Wang, Y., Xu, K., Bai, G., Huang, L., Wu, Q., Pan, W., et al. (2014). Synthesis and antifungal activity of novel triazole compounds containing piperazine moiety. Molecules, 19(8), 11333\u201311340. https:\/\/doi.org\/10.3390\/molecules190811333","journal-title":"Molecules"},{"issue":"4","key":"10051_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., et al. (2016). Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 63(4), e1\u2013e60. https:\/\/doi.org\/10.1093\/cid\/ciw326","journal-title":"Clinical Infectious Diseases"},{"issue":"15","key":"10051_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/cid\/civ571","volume":"61","author":"MH Miceli","year":"2015","unstructured":"Miceli, M. H., & Kauffman, C. A. (2015). Isavuconazole: A new broad-spectrum triazole antifungal agent. Clinical Infectious Diseases, 61(15), 1558\u20131565. https:\/\/doi.org\/10.1093\/cid\/civ571","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10051_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., et al. (2007). Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New England Journal of Medicine, 356(4), 348\u2013359. https:\/\/doi.org\/10.1056\/NEJMoa061094","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10051_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/mmy\/myy052","volume":"57","author":"JD Jenks","year":"2019","unstructured":"Jenks, J. D., Mehta, S. R., & Hoenigl, M. (2019). Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? Medical Mycology, 57(Suppl 2), 168\u2013178. https:\/\/doi.org\/10.1093\/mmy\/myy052","journal-title":"Medical Mycology"},{"issue":"2","key":"10051_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1517\/14656566.4.2.147","volume":"4","author":"JC Gallagher","year":"2003","unstructured":"Gallagher, J. C., Dodds Ashley, E. S., Drew, R. H., & Perfect, J. R. (2003). Antifungal pharmacotherapy for invasive mould infections. Expert Opinion on Pharmacotherapy, 4(2), 147\u2013164. https:\/\/doi.org\/10.1517\/14656566.4.2.147","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"10051_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21542\/gcsp.2017.11","volume":"2017","author":"M Salem","year":"2017","unstructured":"Salem, M., Reichlin, T., Fasel, D., & Leuppi-Taegtmeyer, A. (2017). Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports. Global Cardiology Science and Practice, 2017(2), 1\u20135. https:\/\/doi.org\/10.21542\/gcsp.2017.11","journal-title":"Global Cardiology Science and Practice"},{"issue":"3","key":"10051_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12245-008-0052-0","volume":"1","author":"JM Prosser","year":"2008","unstructured":"Prosser, J. M., Mills, A., Rhim, E. S., & Perrone, J. (2008). Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. International Journal of Emergency Medicine, 1(3), 217\u2013220. https:\/\/doi.org\/10.1007\/s12245-008-0052-0","journal-title":"International Journal of Emergency Medicine"},{"issue":"14","key":"10051_CR12","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1080\/10428194.2019.1639165","volume":"60","author":"JN Barreto","year":"2019","unstructured":"Barreto, J. N., Cullen, M. W., Mara, K. C., Grove, M. E., Sierzchulski, A. G., Dahl, N. J., et al. (2019). QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia. Leukemia & Lymphoma, 60(14), 3512\u20133520. https:\/\/doi.org\/10.1080\/10428194.2019.1639165","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10051_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/europace\/eut214","volume":"16","author":"G Sarganas","year":"2014","unstructured":"Sarganas, G., Garbe, E., Klimpel, A., Hering, R. C., Bronder, E., & Haverkamp, W. (2014). Epidemiology of symptomatic drug-induced long QT syndrome and torsade depointes in Germany. Europace, 16(1), 101\u2013108. https:\/\/doi.org\/10.1093\/europace\/eut214","journal-title":"Europace"},{"issue":"2","key":"10051_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2125.2012.04415.x","volume":"75","author":"RR Shah","year":"2013","unstructured":"Shah, R. R. (2013). Drug-induced QT interval prolongation: Does ethnicity of the thorough QT study population matter? British Journal of Clinical Pharmacology, 75(2), 347\u2013358. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04415.x","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10051_CR15","doi-asserted-by":"publisher","first-page":"204209862211250","DOI":"10.1177\/20420986221125006","volume":"13","author":"S Lucas","year":"2022","unstructured":"Lucas, S., Ailani, J., Smith, T. R., Abdrabboh, A., Xue, F., & Navetta, M. S. (2022). Pharmacovigilance: Reporting requirements throughout a product\u2019s lifecycle. Therapeutic Advances in Drug Safety, 13, 20420986221125010. https:\/\/doi.org\/10.1177\/20420986221125006","journal-title":"Therapeutic Advances in Drug Safety"},{"key":"10051_CR16","unstructured":"FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Retrieved July 23, 2024."},{"key":"10051_CR17","doi-asserted-by":"publisher","first-page":"107818","DOI":"10.1016\/j.intimp.2021.107818","volume":"98","author":"H Li","year":"2021","unstructured":"Li, H., Sun, X., Sun, D., Zhao, J., Xu, Z. M., Zhao, P., et al. (2021). Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. International Immunopharmacology, 98, 107818. https:\/\/doi.org\/10.1016\/j.intimp.2021.107818","journal-title":"International Immunopharmacology"},{"key":"10051_CR18","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"CZ Zhou","year":"2023","unstructured":"Zhou, C. Z., Peng, S. K., Lin, A. Q., Jiang, A. M., Peng, Y. X., Gu, T. Q., et al. (2023). Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine, 59, 101967. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101967","journal-title":"EClinicalMedicine"},{"key":"10051_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.18433\/jpps32867","volume":"25","author":"ZC Yu","year":"2022","unstructured":"Yu, Z. C., & Liao, X. L. (2022). Torsade de pointes\/QT prolongation associated with antifungal triazoles: A pharmacovigilance study based on the U.S. FDA Adverse Event Reporting System (FAERS). Journal of Pharmacy and Pharmaceutical Sciences, 25, 237\u2013243. https:\/\/doi.org\/10.18433\/jpps32867","journal-title":"Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"4","key":"10051_CR20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"S Cirmi","year":"2020","unstructured":"Cirmi, S., El Abd, A., Letinier, L., Navarra, M., & Salvo, F. (2020). Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA adverse event reporting system database (FAERS). Cancers, 12(4), 826. https:\/\/doi.org\/10.3390\/cancers12040826","journal-title":"Cancers"},{"issue":"7","key":"10051_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","volume":"30","author":"P Mozzicato","year":"2007","unstructured":"Mozzicato, P. (2007). Standardised MedDRA queries: Their role in signal detection. Drug Safety, 30(7), 617\u2013619. https:\/\/doi.org\/10.2165\/00002018-200730070-00009","journal-title":"Drug Safety"},{"key":"10051_CR22","doi-asserted-by":"publisher","first-page":"1259611","DOI":"10.3389\/fphar.2023.1259611","volume":"14","author":"SX Chai","year":"2023","unstructured":"Chai, S. X., Wang, H. L., Dong, J., Qin, C. M., Du, D., Wang, Y. L., et al. (2023). Drug-induced QT prolongation and torsade de pointes: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. Frontiers in Pharmacology, 14, 1259611. https:\/\/doi.org\/10.3389\/fphar.2023.1259611","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10051_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M., & Grundmark, B. (2020). Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations. Drug Safety, 43(5), 479\u2013487. https:\/\/doi.org\/10.1007\/s40264-020-00911-w","journal-title":"Drug Safety"},{"issue":"1","key":"10051_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-022-02713-6","volume":"21","author":"XJ Guo","year":"2023","unstructured":"Guo, X. J., Cai, X. T., Rong, Z. X., Zhang, Y. P., Wen, Y. X., Bai, X., et al. (2023). Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies\u2014pharmacovigilance database analysis with real-world data validation. BMC Medicine, 21(1), 1\u201312. https:\/\/doi.org\/10.1186\/s12916-022-02713-6","journal-title":"BMC Medicine"},{"issue":"2","key":"10051_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie, J. L. (2019). Case-non-case studies: Principle, methods, bias and interpretation. Th\u00e9rapie, 74(2), 225\u2013232. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006","journal-title":"Th\u00e9rapie"},{"key":"10051_CR26","doi-asserted-by":"publisher","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","volume":"50","author":"YD Yan","year":"2022","unstructured":"Yan, Y. D., Zhao, Y., Zhang, C., Fu, J., Su, Y. J., Cui, X. L., et al. (2022). Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine, 50, 101535. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101535","journal-title":"EClinicalMedicine"},{"key":"10051_CR27","doi-asserted-by":"publisher","first-page":"e76230","DOI":"10.7554\/eLife.76230","volume":"11","author":"HR Jia","year":"2022","unstructured":"Jia, H. R., Liu, Y., Li, X. K., Li, H., Pan, Y., Hu, C. X., et al. (2022). Windborne migration amplifies insect-mediated pollination services. eLife, 11, e76230. https:\/\/doi.org\/10.7554\/eLife.76230","journal-title":"eLife"},{"issue":"1149","key":"10051_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","volume":"97","author":"R Khatib","year":"2021","unstructured":"Khatib, R., Sabir, F. R. N., Omari, C., Pepper, C., & Tayebjee, M. H. (2021). Managing drug-induced QT prolongation in clinical practice. Postgraduate Medical Journal, 97(1149), 452\u2013458. https:\/\/doi.org\/10.1136\/postgradmedj-2020-138661","journal-title":"Postgraduate Medical Journal"},{"issue":"10","key":"10051_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40264-015-0316-6","volume":"38","author":"MN Niemeijer","year":"2015","unstructured":"Niemeijer, M. N., van den Berg, M. E., Eijgelsheim, M., Rijnbeek, P. R., & Stricker, B. H. (2015). Pharmacogenetics of drug-induced QT interval prolongation: An update. Drug Safety, 38(10), 855\u2013867. https:\/\/doi.org\/10.1007\/s40264-015-0316-6","journal-title":"Drug Safety"},{"issue":"7","key":"10051_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1345\/aph.1G741","volume":"40","author":"PC Pham","year":"2006","unstructured":"Pham, P. C. (2006). Long Qtc interval and torsade de pointes caused by fluconazole. Annals of Pharmacotherapy, 40(7), 1456\u20131461. https:\/\/doi.org\/10.1345\/aph.1G741","journal-title":"Annals of Pharmacotherapy"},{"issue":"5","key":"10051_CR31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.mayocpiqo.2020.05.006","volume":"4","author":"HR Teaford","year":"2020","unstructured":"Teaford, H. R., Abu Saleh, O. M., Villarraga, H. R., Enzler, M. J., & Rivera, C. G. (2020). The many faces of itraconazole cardiac toxicity. Mayo Clinic Proceedings Innovations Quality & Outcomes, 4(5), 588\u2013594. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.05.006","journal-title":"Mayo Clinic Proceedings Innovations Quality & Outcomes"},{"issue":"1","key":"10051_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1399-3062.2006.00160.x","volume":"9","author":"JA Philips","year":"2007","unstructured":"Philips, J. A., Marty, F. M., Stone, R. M., Koplan, B. A., Katz, J. T., & Baden, L. R. (2007). Torsades de pointes associated with voriconazole use. Transplant Infectious Disease, 9(1), 33\u201336. https:\/\/doi.org\/10.1111\/j.1399-3062.2006.00160.x","journal-title":"Transplant Infectious Disease"},{"issue":"8","key":"10051_CR33","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/jac\/dkx122","volume":"72","author":"NN Pettit","year":"2017","unstructured":"Pettit, N. N., Miceli, M. H., Rivera, C. G., Narayanan, P. P., Perissinotti, A. J., Hsu, M., et al. (2017). Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. Journal of Antimicrobial Chemotherapy, 72(8), 2355\u20132358. https:\/\/doi.org\/10.1093\/jac\/dkx122","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10051_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.620","volume":"101","author":"J Keirns","year":"2017","unstructured":"Keirns, J., Desai, A., Kowalski, D., Lademacher, C., Mujais, S., Parker, B., et al. (2017). QT interval shortening with isavuconazole: In vitro and in vivo effects on cardiac repolarization. Clinical Pharmacology and Therapeutics, 101(6), 782\u2013790. https:\/\/doi.org\/10.1002\/cpt.620","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10051_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.12731","volume":"61","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff, S. C., Bassetti, M., D\u00f6rfel, D., Hagel, S., Lehners, N., Plis, A., et al. (2018). Isavuconazole shortens the QT interval. Mycoses, 61(4), 256\u2013260. https:\/\/doi.org\/10.1111\/myc.12731","journal-title":"Mycoses"},{"key":"10051_CR36","unstructured":"Woosley, R. L., Heise, C. W., Gallo, T., Woosley, R. D., Lambson, J., Romero, K. A. QT drugs List. https:\/\/www.crediblemeds.org\/. Retrieved August 10, 2024."},{"key":"10051_CR37","unstructured":"Changes Made to CredibleMeds Lists (Mar 1, 2015). https:\/\/crediblemeds.org\/blog\/changes-made-crediblemeds-lists. Retrieved August 10, 2024."},{"issue":"1","key":"10051_CR38","doi-asserted-by":"publisher","first-page":"e12888","DOI":"10.1111\/anec.12888","volume":"27","author":"N Mantri","year":"2022","unstructured":"Mantri, N., Lu, M., Zaroff, J. G., Risch, N., Hoffmann, T., Oni-Orisan, A., et al. (2022). Torsade de pointes: A nested case-control study in an integrated healthcare delivery system. Annals of Noninvasive Electrocardiology, 27(1), e12888. https:\/\/doi.org\/10.1111\/anec.12888","journal-title":"Annals of Noninvasive Electrocardiology"},{"key":"10051_CR39","doi-asserted-by":"publisher","first-page":"644279","DOI":"10.3389\/fcvm.2021.644279","volume":"8","author":"S Costa","year":"2021","unstructured":"Costa, S., Saguner, A. M., Gasperetti, A., Akdis, D., Brunckhorst, C., & Duru, F. (2021). The link between sex hormones and susceptibility to cardiac arrhythmias: From molecular basis to clinical implications. Frontiers in Cardiovascular Medicine, 8, 644279. https:\/\/doi.org\/10.3389\/fcvm.2021.644279","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10051_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40801-022-00341-3","volume":"10","author":"M Gustafsson","year":"2023","unstructured":"Gustafsson, M., Altufaili, M., & Sj\u00f6LANDER, M. (2023). Prevalence of drugs and drug combinations that increase risk of prolonged QT time among people with major neurocognitive disorder living in Sweden: A cross-sectional registry study. Drugs in the Real World Outcomes, 10(1), 61\u201368. https:\/\/doi.org\/10.1007\/s40801-022-00341-3","journal-title":"Drugs in the Real World Outcomes"},{"issue":"12","key":"10051_CR41","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/cvr\/27.12.2186","volume":"27","author":"L Carlsson","year":"1993","unstructured":"Carlsson, L., Abrahamsson, C., Andersson, B., Duker, G., & Schiller-Linhardt, G. (1993). Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovascular Research, 27(12), 2186\u20132193. https:\/\/doi.org\/10.1093\/cvr\/27.12.2186","journal-title":"Cardiovascular Research"},{"issue":"8","key":"10051_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., et al. (2010). Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121(8), 1047\u20131060. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192704","journal-title":"Circulation"},{"issue":"2","key":"10051_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bcp.13457","volume":"84","author":"FA Berger","year":"2018","unstructured":"Berger, F. A., Monadian, N., de Groot, N. M. S., Santbergen, B., van der Sijs, H., Becker, M. L., et al. (2018). QTc prolongation during ciprofloxacin and fluconazole combination therapy: Prevalence and associated risk factors. British Journal of Clinical Pharmacology, 84(2), 369\u2013378. https:\/\/doi.org\/10.1111\/bcp.13457","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10051_CR44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","volume":"82","author":"D Zeltser","year":"2003","unstructured":"Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K., & Viskin, S. (2003). Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine Baltimore, 82(4), 282\u2013290. https:\/\/doi.org\/10.1097\/01.md.0000085057.63483.9b","journal-title":"Medicine Baltimore"},{"issue":"1","key":"10051_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12551-022-00929-7","volume":"14","author":"C TeBay","year":"2022","unstructured":"TeBay, C., Hill, A. P., & Windley, M. J. (2022). Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. Biophysical Reviews, 14(1), 353\u2013367. https:\/\/doi.org\/10.1007\/s12551-022-00929-7","journal-title":"Biophysical Reviews"},{"issue":"6 Suppl","key":"10051_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/CCM.0b013e3181de112a","volume":"38","author":"BJ Barnes","year":"2010","unstructured":"Barnes, B. J., & Hollands, J. M. (2010). Drug-induced arrhythmias. Critical Care Medicine, 38(6 Suppl), 188\u2013197. https:\/\/doi.org\/10.1097\/CCM.0b013e3181de112a","journal-title":"Critical Care Medicine"},{"issue":"10","key":"10051_CR47","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/pds.1637","volume":"17","author":"BD Freeman","year":"2008","unstructured":"Freeman, B. D., Dixon, D. J., Coopersmith, C. M., Zehnbauer, B. A., & Buchman, T. G. (2008). Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiology and Drug Safety, 17(10), 971\u2013981. https:\/\/doi.org\/10.1002\/pds.1637","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10051_CR48","unstructured":"Clinical Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry (January 2020). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Retrieved August 10, 2024."},{"issue":"12","key":"10051_CR49","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1086\/508873","volume":"43","author":"RC Owens Jr","year":"2006","unstructured":"Owens, R. C., Jr., & Nolin, T. D. (2006). Antimicrobial-associated QT interval prolongation: Pointes of interest. Clinical Infectious Diseases, 43(12), 1603\u20131611. https:\/\/doi.org\/10.1086\/508873","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10051_CR50","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014). Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology. Journal of Antimicrobial Chemotherapy, 69(5), 1162\u20131176. https:\/\/doi.org\/10.1093\/jac\/dkt508","journal-title":"Journal of Antimicrobial Chemotherapy"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10051-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T03:12:50Z","timestamp":1757646770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10051-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10051"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10051-1","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Ethics approval and consent to participate since data in FAERS are anonymized and publicly available, the requirements for obtaining informed consent and institutional review board approval were waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}